News

Pierre Fabre Selects AGC Biologics as CDMO to Manufacture the Orphan Drug ER-004

News

(SEATTLE), December 21, 2020 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and debilitating genetic disorder. AGC Biologics will manufacture GMP material for the next stage of clinical trial.

Follow Us
Join us on LinkedIn Follow us on Twitter